Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
Journal of Oncology Pharmacy Practice
Published online on October 28, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
ObjectiveAnaplastic lymphoma kinase (ALK) rearrangements are one of the key therapeutic targets in non-small cell lung cancer (NSCLC). Ensartinib, a second-generation ALK tyrosine kinase inhibitor (TKI), was recently approved by the FDA for the treatment ...
ObjectiveAnaplastic lymphoma kinase (ALK) rearrangements are one of the key therapeutic targets in non-small cell lung cancer (NSCLC). Ensartinib, a second-generation ALK tyrosine kinase inhibitor (TKI), was recently approved by the FDA for the treatment ...